<i>CLU</i> polymorphisms and plasma clusterin levels in patients with multiple sclerosis: association with disability scores, progression rate and fingolimod therapy
These findings suggest that <i>CLU</i> SNPs and plasma clusterin concentrations could serve as significant biomarkers at different stages of MS.
Authors
- Osman Oğuzhan Kılıç (ORCID: https://orcid.org/0000-0003-4779-8390)
- Semra Mungan (ORCID: https://orcid.org/0000-0002-6469-5185)
- Birsen Can Demirdöğen (ORCID: https://orcid.org/0000-0002-1536-6123)
- Şeref Demirkaya (ORCID: https://orcid.org/0000-0002-0243-6807)
Institutions
- TOBB University of Economics and Technology (TR)
- University of Health Science (KH)
- Sağlık Bilimleri Üniversitesi (TR)
- Ankara Bilkent City Hospital (TR)
Publication Details
- Journal
- Neurological Research
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1080/01616412.2025.2497477
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00